Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Viviana Del Tejo"'
Autor:
David F. McDermott, Michael B. Atkins, Brian Stwalley, Viviana Del Tejo, Stephen Huo, Laurence Albiges, Bernard Escudier, Hans J. Hammers, Brian I. Rini, Toni K. Choueiri, Elizabeth R. Plimack, Martin H. Voss, Yoshihiko Tomita, Chung-Han Lee, Nizar M. Tannir, Robert J. Motzer, Lillian Werner, Thomas Powles, Charlene M. Mantia, Opeyemi A. Jegede, Meredith M. Regan
Supplementary Data from Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e49ca13be123ef92c935f63a88bc82d
https://doi.org/10.1158/1078-0432.22483101.v1
https://doi.org/10.1158/1078-0432.22483101.v1
Autor:
Daniel M, Geynisman, Ella X, Du, Xiaoran, Yang, Selvam R, Sendhil, Viviana Del, Tejo, Keith A, Betts, Stephen, Huo
Publikováno v:
Future Oncology. 18:1219-1234
Aims: To assess grade 3/4 adverse events (AEs) and costs of first-line nivolumab plus ipilimumab versus sunitinib in advanced or metastatic renal cell carcinoma. Methods: Individual patient data from the all treated population in the CheckMate 214 tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::266d5aea39b39f6ad03296da75117833
https://doi.org/10.2217/fon-2021-1109
https://doi.org/10.2217/fon-2021-1109
Autor:
Bradley McGregor, Daniel M. Geynisman, Mauricio Burotto, Cristina Suárez, Maria T. Bourlon, Pedro C. Barata, Shuchi Gulati, Stephen Huo, Flavia Ejzykowicz, Steven I. Blum, Viviana Del Tejo, Melissa Hamilton, Jessica R. May, Ella X. Du, Aozhou Wu, Pavol Kral, Cristina Ivanescu, Andi Chin, Keith A. Betts, Chung-Han Lee, Toni K. Choueiri, David Cella, Camillo Porta
Publikováno v:
European Urology Oncology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cbf4b42a283a34e4313b7163bcedee06
https://doi.org/10.1016/j.euo.2023.01.012
https://doi.org/10.1016/j.euo.2023.01.012
Autor:
Bradley McGregor, Daniel M Geynisman, Mauricio Burotto, Camillo Porta, Cristina Suarez, Maria T Bourlon, Viviana Del Tejo, Ella X Du, Xiaoran Yang, Selvam R Sendhil, Keith A Betts, Stephen Huo
Publikováno v:
Scientia
Background Despite 4 approved combination regimens in the first-line setting for advanced renal cell carcinoma (aRCC), adverse event (AE) costs data are lacking. Materials and Methods A descriptive analysis on 2 AE cost comparisons was conducted usin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24a1624d6b56737a87630493fac99671
https://hdl.handle.net/11351/9391
https://hdl.handle.net/11351/9391
Autor:
Daniel M. Geynisman, Mauricio Burotto, Camillo Porta, Cristina Suarez, Maria T. Bourlon, Stephen Huo, Viviana Del Tejo, Ella X. Du, Xiaoran Yang, Keith A. Betts, Toni K. Choueiri, Bradley McGregor
Publikováno v:
Scientia
Advanced Renal Cell Carcinoma; Adverse Events; Nivolumab Carcinoma de células renales avanzado; Eventos adversos; Nivolumab Carcinoma de cèl·lules renals avançat; Esdeveniments adversos; Nivolumab Background and Objectives Novel immunotherapy-bas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f21994a622b2cdcb524ad4515e5fa0de
https://pubmed.ncbi.nlm.nih.gov/35696045
https://pubmed.ncbi.nlm.nih.gov/35696045
Autor:
Moshe Chaim Ornstein, Lisa Rosenblatt, Flavia Ejzykowicz, Sarah Guttenplan, Viviana Del Tejo, Xin Yin, Kathleen M. Beusterien, deMauri S Mackie, Oliver Will, Grace Skiles, Marc DeCongelio, Steven S. Senglaub
Publikováno v:
Journal of Clinical Oncology. 41:630-630
630 Background: The introduction of immunotherapies has changed the first-line treatment landscape for advanced/metastatic renal cell carcinoma (aRCC). This study examines patient preferences in this rapidly changing environment to better understand
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::643134adaedf9fc4b6085a7a76824c46
https://doi.org/10.1200/jco.2023.41.6_suppl.630
https://doi.org/10.1200/jco.2023.41.6_suppl.630
Autor:
Brian Stwalley, Chung-Han Lee, Yoshihiko Tomita, Bernard Escudier, Hans J. Hammers, David F. McDermott, Thomas Powles, Martin H. Voss, Elizabeth R. Plimack, Viviana Del Tejo, Toni K. Choueiri, Meredith M. Regan, Michael B. Atkins, Laurence Albiges, Lillian Werner, Robert J. Motzer, Opeyemi Jegede, Brian I. Rini, Charlene Mantia, Nizar M. Tannir, S. Huo
Publikováno v:
Clin Cancer Res
Purpose: Patients discontinuing immuno-oncology regimens may experience periods of disease control without need for ongoing anticancer therapy, but toxicity may persist. We describe treatment-free survival (TFS), with and without toxicity. Patients a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c25785260ba50cded3b033dc3b62638b
https://pubmed.ncbi.nlm.nih.gov/34845347
https://pubmed.ncbi.nlm.nih.gov/34845347
Autor:
Daniel M. Geynisman, Jonathan K. Kish, Angelica Falkenstein, Stephen Huo, Viviana Del Tejo, Lisa Rosenblatt, Sarah Guttenplan, Alexandrina Balanean, Bruce A. Feinberg
Publikováno v:
Journal of Clinical Oncology. 40:4548-4548
4548 Background: In 1L therapy for aRCC, nivolumab plus ipilimumab (NIVO+IPI) and pembrolizumab plus axitinib (PEM+AXI) have demonstrated significantly improved clinical outcomes versus sunitinib in phase III trials. African American/Black (AA) patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d64f07551d0911422355c19b404bbbd7
https://doi.org/10.1200/jco.2022.40.16_suppl.4548
https://doi.org/10.1200/jco.2022.40.16_suppl.4548
Autor:
Daniel M. Geynisman, Jonathan Kish, Angelica Falkenstein, Viviana Del Tejo, Stephen Huo, Alexandrina Balanean, Bruce A. Feinberg
Publikováno v:
Journal of Clinical Oncology. 40:311-311
311 Background: The immuno-oncology (IO) therapy combination nivolumab + ipilimumab, and the IO-tyrosine kinase inhibitor (TKI) combination pembrolizumab + axitinib, received US FDA approvals in 2018 and 2019, respectively, as first-line (1L) therapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::80d5e82f25794d016d69ba73d9c4e25a
https://doi.org/10.1200/jco.2022.40.6_suppl.311
https://doi.org/10.1200/jco.2022.40.6_suppl.311
Autor:
Brian Stwalley, Philip K Chan, Liwei Chen, Gurjyot K. Doshi, Nicholas J. Robert, S. Huo, Viviana Del Tejo, Daniel M. Geynisman
Publikováno v:
Journal of Clinical Oncology. 39:305-305
305 Background: Nivolumab plus ipilimumab (NIVO+IPI), a first-in-class combination immunotherapy, was approved by the US Food and Drug Administration in April 2018 for the treatment of intermediate- or poor-risk advanced renal cell carcinoma (RCC), a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::316a127300fe1b40694c93a3250c3faa
https://doi.org/10.1200/jco.2020.39.28_suppl.305
https://doi.org/10.1200/jco.2020.39.28_suppl.305